

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/912,957	07/25/2001 / 7590 12/09/2002	Pierre Barbier	20713	7137
HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT 340 KINGSLAND STREET			EXAMINER	
			PESELEV, ELLI	
NUTLEY, NJ	0/110		ART UNIT PAPER NUMBER	
			1623	10
			DATE MAILED: 12/09/2002	10

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati n N .	Applicant(s)
	Office Action Summan	09/912,957	BARBIER ET AL.
	Office Action Summary	Examiner	Art Unit
	The MAILING DAYS	Elli Peselev	1623
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the	correspondence address
- Exter after - If the - If NO - Failur - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1: SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing of patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti y within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from	mely filed ys will be considered timely. In the mailing date of this communication.
1)🖂	Responsive to communication(s) filed on 04 N	lovember 2002	
2a) <u></u>		is action is non-final.	
3)	Since this application is in condition for allowardlosed in accordance with the practice under		
,—	closed in accordance with the practice under lon of Claims	Ex parte Quayle, 1935 C.D. 11, 4	rosecution as to the merits is 453 O.G. 213.
4)⊠	Claim(s) <u>1,2,8,10-15,17,18 and 20-46</u> is/are pe	ending in the application.	
	a) Of the above claim(s) is/are withdraw		
	Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>1, 2, 8, 10-15, 17, 18 and 20-45</u> is/are	rejected.	
	Claim(s) is/are objected to.	•	
8) 🗌 (	Claim(s) are subject to restriction and/or	election requirement.	
Application	on Papers		
	he specification is objected to by the Examiner.		
10)∐ T	he drawing(s) filed on is/are: a)∏ accept	ed or b)⊡ objected to by the Exar	miner.
44) 🗆 🖚	Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).
11)[11	he proposed drawing correction filed on	is: a)☐ approved b)☐ disappro	ved by the Examiner.
40)[] =	If approved, corrected drawings are required in repl	y to this Office action.	
	ne oath or declaration is objected to by the Exa	miner.	
	der 35 U.S.C. §§ 119 and 120		
13) A	acknowledgment is made of a claim for foreign i	priority under 35 U.S.C. § 119(a)	-(d) or (f).
	All b) Some * c) None of:		
1	. Certified copies of the priority documents		
2	. Certified copies of the priority documents	have been received in Applicatio	n No
	. Copies of the certified copies of the priority application from the International Bure the attached detailed Office action for a list of	y documents have been received	d in this National Stage
14) <u></u> Acl	knowledgment is made of a claim for domestic	priority under 35 U.S.C. & 119(a)	(to a provisional application)
a) [	☐ The translation of the foreign language providence  knowledgment is made of a claim for domestic  knowledgment is made of a claim for down in the claim for down is made of a claim for down in the claim for dow	sional application has been roce	ivad
Notice of Notice of Notice of Notice	f References Cited (PTO-892) f Draftsperson's Patent Drawing Review (PTO-948) ion Disclosure Statement(s) (PTO-1449) Paper No(s)		PTO-413) Paper No(s) tent Application (PTO-152)
Patent and Trade O-326 (Rev. 0	mark Office )4-01) Office Actio	n Summanı	_

Application/Control Number: 09/912,957

Art Unit: 1623

Claims 20-23 and 29-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

There is no antecedent basis in claims 17 and 28 for the terminology "the lipase inhibitor" as set forth in claims 20-23 and 29-31.

Claims 1-2, 8, 10-15, 17-18 and 20-46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gregg et al (U.S. Patent No. 5,883,109).

Gregg et al disclose that bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex and tetrahydrolistatin (orlistat) are all useful as cholesterol lowering drugs (column 22, lines 42-55). A person having ordinary skill in the art at the time the instant invention was made would have been motivated to combine orlistat with a bile acid sequestrant because such a person would have expected the resulting composition to be useful in lowering cholesterol.

Applicant's arguments filed November 4, 2002 have been fully considered but they are not persuasive insofar as the above rejections relate to the claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is 703-308-4616. The examiner can normally be reached on weekdays 8.30 a.m. - 5.00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 703-308-4624. The fax phone numbers for the organization where this application or proceeding is assigned are 703-

Application/Control Number: 09/912,957

Art Unit: 1623

308-4556 for regular communications and 703-308-4556 for After Final

communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Elli Peselev December 4, 2002

> ELLI PESELEV PRIMARY EXAMINER GROUP 1800

Page 3